Loading clinical trials...
Loading clinical trials...
A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different LNP Formulations of mRNA Vaccines Using the RSV Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
Conditions
Interventions
RSV vaccine formulation 1 dose
RSV vaccine formulation 2 dose
+6 more
Locations
6
Australia
Site # 0361003
Wollongong, New South Wales, Australia
Site # 0361006
Brisbane, Queensland, Australia
Site # 0361005
Morayfield, Queensland, Australia
Site # 0361004
Southport, Queensland, Australia
Site # 0361002
Bayswater, Victoria, Australia
Site # 0361001
Camberwell, Victoria, Australia
Start Date
July 14, 2025
Primary Completion Date
February 26, 2026
Completion Date
February 26, 2026
Last Updated
September 16, 2025
NCT07164430
NCT05639894
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions